...Thank you, Carrie. Good afternoon, everyone, and thank you for joining us on the call. First quarter of 2023 was another significant period for Lexicon as we continue to advance in both of our lead programs, sotagliflozin, our dual SGLT1/2 inhibitor that we're developing for heart failure, and LX9211, our AAK1 inhibitor that we're developing for neuropathic pain. Starting with LX9211 program for neuropathic pain. As many of you know, we reported on the results of 2 Phase II proof-of-concept studies last year in diabetic peripheral neuropathic pain and postherpetic neuralgia. Bolstered by these results, we have continued to move forward with development plans for late-stage development and expect to have feedback from the FDA on these plans in the second quarter of this year. Turning to sotagliflozin. As shared in our last quarterly call, we had our late cycle review meeting with FDA late February for our NDA for the treatment of heart failure. The agency indicated that there were no substantial...
